v3.26.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 6. Commitments and Contingencies

The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of March 31, 2026 and December 31, 2025 was $10,328 and $12,065, respectively, comprised of the following:

 

 

March 31,
2026

 

 

December 31,
2025

 

Arcutis Biotherapeutics, Inc.

 

$

1,585

 

 

$

3,171

 

Ardelyx, Inc.

 

 

1,494

 

 

 

1,494

 

Wilbur-Ellis Holdings II, LLC

 

 

1,236

 

 

 

1,224

 

ReFocus Management Services, LLC

 

 

911

 

 

 

 

Treace Medical Concepts, Inc.

 

 

753

 

 

 

753

 

Plastic Management, LLC

 

 

633

 

 

 

633

 

Quantcast Corporation

 

 

519

 

 

 

434

 

Stella & Chewy's LLC

 

 

509

 

 

 

429

 

The Townsend Company, LLC

 

 

334

 

 

 

359

 

Alkeme Intermediary Holdings, LLC

 

 

330

 

 

 

681

 

Pinnacle Fertility, Inc.

 

 

273

 

 

 

273

 

Western Veterinary Partners LLC

 

 

264

 

 

 

556

 

Nexus Intermediate III, LLC

 

 

170

 

 

 

278

 

CVAUSA Management, LLC

 

 

157

 

 

 

162

 

Southern Orthodontics Partners Management, LLC

 

 

156

 

 

 

329

 

Sherwood Management Co., Inc.

 

 

147

 

 

 

237

 

World Insurance Associates, LLC

 

 

135

 

 

 

148

 

United Digestive MSO Parent, LLC

 

 

135

 

 

 

135

 

AAH Topco, LLC

 

 

130

 

 

 

173

 

Foundation Consumer Brands, LLC

 

 

125

 

 

 

125

 

Crewline Buyer, Inc.

 

 

122

 

 

 

122

 

Exactcare Parent, Inc.

 

 

81

 

 

 

81

 

Medrina, LLC

 

 

79

 

 

 

79

 

MRI Software LLC

 

 

50

 

 

 

54

 

WALCO Funding, LLC

 

 

 

 

 

135

 

Total Commitments

 

$

10,328

 

 

$

12,065

 

 

The credit agreements governing the above loan commitments contain customary lending provisions and/or are subject to the respective portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of March 31, 2026 and December 31, 2025, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment.

In the normal course of our business, we invest or trade in various financial instruments and may enter into various investment activities with off-balance sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of off-balance sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Consolidated Statements of Assets and Liabilities. As of March 31, 2026, we held no such contracts.

 

From time to time, the Company may become a party to certain legal proceedings incidental to the normal course of its business. As of March 31, 2026 and December 31, 2025, management is not aware of any material pending or threatened litigation that would require accounting recognition or financial statement disclosure.